Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced several strategic leadership appointments within its Drug Product team. These ...

Varda Space Industries announced a Series C fundraising round today, bringing the total amount of capital raised by the microgravity-enabled life sciences company to $329 million. The $187 million ...

Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage ...

IVEN Shines at CPHI China 2025 IVEN logo IVEN factory SHANGHAI, SHANGHAI, CHINA, July 5, 2025 /EINPresswire / -- As the global p ...

Makary and Center for Biologics Evaluation and Research Director Vinay Prasad unveiled a new framework in the New England Journal of Medicine on May 20 requiring a stronger evidence base for boosters ...

What's driving this $370 million transformation? The global residual DNA testing market, valued at US$0.27 billion in 2024, ...

Opportunities in healthcare cold chain logistics include the rise in demand for biologics and personalized medicines, driven ...

The Riverview site provides comprehensive drug substance development and manufacturing services, including spec ...

FDA requires updated warning about rare heart risk with COVID shots Cases of myocarditis are more severe and more common after a COVID infection than after receiving the COVID vaccine, health ...